Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML

View Full Paper
Ask AI
Bookmark
Share

Authors

ISIrtiza SheikhRRReeja RajSCSamanta Catueno

Discussion

Loading...

Member takes

Overview

Retrospective review reveals FLAG-IDA-venetoclax improves engraftment and reduces graft-versus-host disease risk in pediatric AML patients.

Key Points

  • FLAG-IDA-venetoclax leads to effective stem cell transplantation outcomes and high remission rates.
  • Overall, 83% of patients underwent matched unrelated donor SCT with manageable therapy-related adverse events.
  • Engraftment was rapid with a median of 16.5 days for neutrophils and no incidences of acute GVHD reported.
  • This regimen supports the potential for safe and effective transition to SCT in high-risk pediatric AML cases.

Cite This Study

Sheikh et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d88chttps://doi.org/10.1182/blood-2025-5156
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FLAG-mitoxantrone combined with low-dose venetoclax (7 Days): A highly efficient regimen and excellent bridge for allogeneic hematopoietic transplant for newly diagnosed and relapsed/refractory AML.2025
  2. 2High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen2025
  3. 3Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation2025
  4. 4Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study2025
  5. 5Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed Acute Myeloid Leukemia and therapy-related myeloid diseases2025